This paradigm could also apply to other ADC cancer therapeutics if the target antigen exists in both membrane-bound and secreted forms, and may explain why TisVed showed therapeutic potential against cervical cancer in similar flank xenograft models, considering the high membrane-bound TF expression in cervical cancer [10,11,12,20]. This evidence concerns the gene TF and cancer.